Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation

被引：0
|
作者：
G. V. Ramesh Prasad
Jill Beckley
Mohit Mathur
Madhushankar Gunasekaran
Michelle M. Nash
Lindita Rapi
Michael Huang
Jeffrey S. Zaltzman
机构：
[1] University of Toronto,Kidney Transplant Program, St. Michael’s Hospital
[2] University of Toronto,Department of Medicine
来源：
BMC Infectious Diseases | / 19卷
关键词：
Adverse effects; Hyperkalemia; Leukopenia;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation
    Prasad, G. V. Ramesh
    Beckley, Jill
    Mathur, Mohit
    Gunasekaran, Madhushankar
    Nash, Michelle M.
    Rapi, Lindita
    Huang, Michael
    Zaltzman, Jeffrey S.
    BMC INFECTIOUS DISEASES, 2019, 19 (1)
  • [2] Atovaquone versus trimethoprim-sulfamethoxazole as Pneumocystis jirovecii pneumonia prophylaxis following renal transplantation
    Gabardi, Steven
    Millen, Peter
    Hurwitz, Shelley
    Martin, Spencer
    Roberts, Keri
    Chandraker, Anil
    CLINICAL TRANSPLANTATION, 2012, 26 (03) : E184 - E190
  • [3] LIFELONG PROPHYLAXIS WITH TRIMETHOPRIM-SULFAMETHOXAZOLE FOR PREVENTION OF OUTBREAK OF PNEUMOCYSTIS JIROVECII PNEUMONIA IN KIDNEY TRANSPLANT RECIPIENTS
    Goto, Norihiko
    Takahashi-Nakazato, Ai
    Futamura, Kenta
    Okada, Manabu
    Tsujita, Makoto
    Hiramitsu, Takahisa
    Narumi, Shunji
    Oka, Shinichi
    Watarai, Yoshihiko
    TRANSPLANT INTERNATIONAL, 2017, 30 : 309 - 309
  • [4] Reduction of Pneumocystis jirovecii pneumonia and bloodstream infections by trimethoprim-sulfamethoxazole prophylaxis in patients with rheumatic diseases
    Honda, N.
    Tagashira, Y.
    Kawai, S.
    Kobayashi, T.
    Yamamoto, M.
    Shimada, K.
    Yokogawa, N.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2021, 50 (05) : 365 - 371
  • [5] Clinical Characteristics and Epidemiological Analysis of Pneumocystis Jirovecii Pneumonia Infection in Kidney Transplant Patients with Trimethoprim-Sulfamethoxazole Dose Reduction Prophylaxis Strategy
    Shan, Wenya
    Wang, Liangping
    Qin, Jiayi
    Peng, Wenhan
    Ma, Kuifen
    INFECTION AND DRUG RESISTANCE, 2024, 17 : 2299 - 2306
  • [6] Once weekly trimethoprim-sulfamethoxazole for Pneumocystis jirovecii pneumonia prophylaxis in children with cancer
    McMullan, Brendan
    JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2014, 50 (06) : 491 - 491
  • [7] 'Once weekly trimethoprim-sulfamethoxazole for Pneumocystis jirovecii pneumonia prophylaxis in children with cancer'
    McMullan, Brendan
    JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2014, 50 (05) : 415 - 415
  • [8] Methotrexate and Trimethoprim-Sulfamethoxazole for Pneumocystis pneumonia Prophylaxis
    Yamazaki, Hayato
    Nanki, Toshihiro
    Miyasaka, Nobuyuki
    Harigai, Masayoshi
    JOURNAL OF RHEUMATOLOGY, 2011, 38 (04) : 777 - 778
  • [9] A Case of Pneumonia Caused by Pneumocystis jirovecii Resistant to Trimethoprim-Sulfamethoxazole
    Lee, Sang Min
    Cho, Yong Kyun
    Sung, Yon Mi
    Chung, Dong Hae
    Jeong, Sung Hwan
    Park, Jeong-Woong
    Lee, Sang Pyo
    KOREAN JOURNAL OF PARASITOLOGY, 2015, 53 (03): : 321 - 327
  • [10] Tolerability of low-dose sulfamethoxazole/trimethoprim for Pneumocystis jirovecii pneumonia prophylaxis in kidney transplant recipients
    Zmarlicka, Monika
    Martin, Spencer T.
    Cardwell, Sophia M.
    Nailor, Michael D.
    PROGRESS IN TRANSPLANTATION, 2015, 25 (03) : 210 - 216
12345